FDA and EMA Regulatory Pathways
The FDA and EMA oversee medical product approvals.
Both agencies aim to protect public health.
Both agencies aim to protect public health.
FDA pathways
- Premarket Approval (PMA) for high‑risk devices.
- 510(k) for moderate‑risk devices that are substantially equivalent to existing ones.
- De Novo for low‑to‑moderate risk devices with no predicate.
- Breakthrough Device Designation speeds up development and review.
- Fast Track and Accelerated Approval are options for drugs with unmet medical need.
EMA pathways
- Centralised Procedure for all high‑risk medicines and some advanced therapies.
- Conditional Marketing Authorisation for early approval of promising therapies.
- Adaptive Pathways allow iterative data collection after conditional approval.
- ** PRIME (PRIority MEdicines)** offers early interaction and accelerated assessment.
Key similarities
Both agencies require robust safety and efficacy data.
Both offer expedited programs for serious conditions.
Both offer expedited programs for serious conditions.
Key differences
The FDA uses a single‑application system for drugs and devices.
The EMA relies on a network of national agencies and the Committee for Medicinal Products for Human Use (CHMP).
The EMA relies on a network of national agencies and the Committee for Medicinal Products for Human Use (CHMP).
Practical tips
- Engage early with regulators to discuss the appropriate pathway.
- Align study designs with agency expectations to avoid delays.
- Use expedited programs when the product addresses an unmet need.
Regulatory pathways shape the route from bench to market.
Understanding them helps bring innovations to patients faster.
Understanding them helps bring innovations to patients faster.